safety of vedolizumab in moderately to severely active CD and studies (Tables 1 and 2). Five of these (brodalumab, MABp1, UC patients who had failed to respond to treatment with at least moxetumomab pasudotox, tildrakizumab, rilotumumab) tran-one conventional or anti-tumor necrosis factor drug.sitioned into Phase 3 studies during the period from late 2012 In late April 2013, Lilly announced that they received Fast to April 2013. Brodalumab (AMG827, Amgen; KHK4827, Track designation from the FDA for ramucirumab, a human Kyowa Hakko Kirin), a human IgG2 targeting the interleu-IgG1 that targets vascular endothelial growth factor receptor-2, kin (IL)-17 receptor, is undergoing evaluation in three Phase and that they initiated a rolling submission of a licensing applica-3 studies (AMAGINE-1, -2, and -3) of patients with psoriasis. tion of the mAb as monotherapy in second-line gastric cancer. The AMAGINE-1 study (NCT01708590) is evaluating the Fast Track designation is given to drugs intended to treat serious efficacy, safety, and effect of withdrawal and retreatment with diseases and fill an unmet medical need. The review of Fast Track brodalumab in patients with moderate-to-severe plaque pso-drugs can be expedited by a rolling submission in which com-riasis. In this study, either of two doses (140 mg or 210 mg) or pleted sections of the application are reviewed by FDA as they are placebo is administered subcutaneously (SC) every two weeks submitted, i.e., FDA does not wait for the entire application to until week 12, when patients are rerandomized to placebo or be submitted before beginning the review. Lilly expects to com-continued treatment. Patients are retreated at return of disease. plete the submission process by the end of 2013. Ramucirumab The estimated primary completion date for the study is March has been evaluated in two Phase 3 studies (NCT00917384, 2014. In the AMAGINE-2 (NCT01708603) and AMAGINE-3 NCT01170663) of patients with gastric cancer. In addition, the (NCT01708603) studies, the efficacy and safety of induction mAb is also undergoing evaluation in Phase 3 studies of non-and four maintenance regimens of brodalumab compared with small cell lung cancer (NCT01168973), hepatocellular carci-placebo and ustekinumab in patients with moderate-to-severe noma (NCT01140347), colorectal cancer (NCT01183780), and plaque psoriasis is being evaluated. These studies have esti-breast cancer (NCT00703326) patients. The primary comple-mated primary completion dates of August and September 2014, tion date for the study in breast cancer is March 2013, with pri-respectively.
mary completion dates scheduled in 2014 for the other studies.A first Phase 3 study (NCT01767857) of MABp1 (Xilonix, In mid-May 2013, Roche announced that obinutuzumab had XBiotech, Inc.), a human mAb targeting IL-1a, was recruit-been granted breakthrough therapy designation by FDA, and ing patients as of March 2013. The study will evaluate overall that marketing applications had been submitted in the US and survival of metastatic colorectal cancer patients with cachexia European Union. Obinutuzumab is a type II anti-CD20 IgG1 who are administered the mAb as a monotherapy. The effects of antibody with reduced fucosylation. The marketing applica-MABp1 administered intravenously (IV) every two weeks, plus tions were based on data from the 3-arm, Phase 3 CLL11 study best supportive care will be compared with those of megestrol (NCT01010061), which compared the combination of either acetate administered daily plus best supportive care. The dif-obinutuzumab or rituximab and chlorambucil to chlorambucil ference between the study arms in median overall survival from alone in patients with previously untreated chronic lymphocytic baseline to 18 mo will be compared. The study has an estimated leukemia. The benefits of the breakthrough therapy designa-primary completion date of April 2014.
tion includes all those provided by the fast track program, but The recombinant immunotoxin moxetumomab pasudotox also more intensive FDA guidance on the drug’s development (CAT-8015, AstraZeneca) is undergoing evaluation in a Phase 3 program. Obinutuzumab is also undergoing evaluation as a study (NCT01829711) of patients with relapsed/refractory hairy treatment for lymphoma. Three Phase 3 studies are on-going: cell leukemia. The study is sponsored by the National Cancer
(1) GADOLIN (NCT01059630), which compares bendamus-Institute (NCI); the mAb is currently licensed to AstraZeneca. In tine with the combination of bendamustine and obinutuzumab in 2004, NCI licensed moxetumomab pasudotox to Genencor, Inc. patients with rituximab-refractory, indolent non-Hodgkin lym-The mAb was then acquired in 2005 by Cambridge Antibody phoma; (2) GOYA (NCT01287741), which compares obinutu-Technology, which was itself acquired by AstraZeneca in 2006. zumab in combination with CHOP chemotherapy to rituximab Moxetumomab pasudotox comprises a mouse disulfide stabilized with CHOP in previously untreated patients with CD20-variable fragment with the variable heavy domain fused with a positive diffuse large B cell lymphoma; and (3) GALLIUM 7-mer linker and the Pseudomonas aeruginosa exotoxin A PE38 (NCT01332968), which compares obinutuzumab in combina-fragment. In the Phase 3 study, patients will receive 40 μg/kg of tion with chemotherapy compared to rituximab with chemother-the immunotoxin administered IV over 30 min on days 1, 3, 5 of apy (CHOP, CVP or bendamustine) followed by obinutuzumab each 28 d cycle until complete response, progressive disease, ini-or rituximab maintenance in patients with untreated advanced tiation of alternate therapy or unacceptable toxicity is observed. indolent non-Hodgkin lymphoma. The primary completion Initiated in March 2013, the study’s estimated primary comple-dates for these studies are January 2015, November 2016 and tion date is December 2014.
March 2022, respectively.Two Phase 3 studies of tildrakizumab (SCH900222/MK-3222,
First Phase 3 Studies for Five mAbsMerck), a humanized mAb targeting the p19 subunit of IL-23, are
recruiting patients. Initiated in December 2012, NCT01722331
is a 64-week study to evaluate the efficacy and safety/tolerability
A total of 30 mAbs that were either developed or in-licensed of SC administration of tildrakizumab in patients with moder-by companies are currently undergoing evaluation in late-stage ate-to-severe chronic plaque psoriasis. Patients receive 100 mg or 514 mAbs Volume 5 issue 4©2013 Landes Bioscience. Do not distribute.
2013年中国单克隆抗体药物市场深度调研报告_经济/市场_经管营销_专业资料。单克隆...年中国单克隆抗体药物行业产品市场价格回顾 第二节 中国单克隆抗体药物行业产品...
临床Ⅰ期与临床Ⅱ期研究 与开发的各类生物技术药物中,抗体药物的品种数量位居...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
北京智道顾问有限责任公司 2013-2017 年中国抗体药物行业现状 与发展趋势及前景预测报告 智库在线(www.zikoo.com)秉承“智通库汇 ”的服务理 念,不断收集和更新...
很大一部分抗体药物都已迈入重磅炸弹行 列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2017年中国抗体药物市场专项调研与发展策略研究报告_经济/市场_经管营销_专业...年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2011-2012 ...
2013-2018 年中国抗体药物行业市场 运行态势及投资前景预测报告 2013-2018 年中国...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
(注:由于多用户报告的各类客户信息关 注点不同,上述所涉及的内容可根据具体需求进行调整) 2013-2018 年中国抗体药物行业市场前瞻及投资咨询报告 目录 第一章 抗体...
很大 一部分抗体药物都已迈入重磅炸弹行列,在 2008 年全球 15 大药品中,抗体...2013 年全球生物制药产业运行总况 第一节 全球生物制药发展回顾 第二节 2012-...
2013-2018年中国单克隆抗体药物行业市场行情动态及未来发展趋势预测分析报告_经济/...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
2013-2018 年中国单克隆抗体药物行 业市场监测与投资前景分析报告 2013-2018 年...全球生物制药发展回顾 第二节 2012-2013 年全球生物制药产业现状综述 一、全球...
热门文档